Grundläggande statistik
| CIK | 1094847 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to OncoVista Innovative Therapies, Inc.
SEC Filings (Chronological Order)
Denna sida innehåller en komplett, kronologisk lista över SEC-arkiveringar, exklusive ägande-arkiveringar som vi tillhandahåller på andra ställen.
| May 9, 2016 |
OncoVista Innovative Therapies 15-12G OMB APPROVAL OMB Number: 3235-0167 Expires: March 31, 2018 Estimated average burden hours per response 1. |
|
| April 27, 2016 |
OVIT / OncoVista Innovative Therapies, Inc. / St George Investments LLC - NONE Passive Investment SC 13G 1 doc1.htm NONE UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. n/a )* Oncovista Innovative Therapies, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 68232J105 (CUSIP Number) April 27, 2016 (Date of Event Which Requires Filing of this Statement) Check the approp |
|
| April 8, 2016 |
OVIT / OncoVista Innovative Therapies, Inc. / Smithline Richard Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) Amendment No. 2 INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1 (b) (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2 OncoVista Innovative Therapies, Inc. (Name of Issuer) Common Stock, $0.001par value per share (Title of Class of Securities) 68232J105 (CUSIP Number) March 21 |
|
| February 4, 2016 |
OVIT / OncoVista Innovative Therapies, Inc. / Smithline Richard Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) Amendment No. 1 INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1 (b) (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2 OncoVista Innovative Therapies, Inc. (Name of Issuer) Common Stock, $0.001par value per share (Title of Class of Securities) 68232J105 (CUSIP Number) December |
|
| November 12, 2015 |
OncoVista Innovative Therapies FORM 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2015 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-28347 ONCOVIST |
|
| September 8, 2015 |
OVIT / OncoVista Innovative Therapies, Inc. / Smithline Richard Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1 (b) (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2 OncoVista Innovative Therapies, Inc. (Name of Issuer) Common Stock, $0.001par value per share (Title of Class of Securities) 68232J105 (CUSIP Number) August 1, 2015 (Date of |
|
| August 14, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2015 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-28347 ONCOVISTA INN |
|
| May 15, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2015 ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-28347 ONCOVISTA IN |
|
| April 15, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2014 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-28347 ONCOVISTA INNOVAT |
|
| March 23, 2015 |
OncoVista Innovative Therapies NT 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check one): x Form 10-K o Form 20-F o Form 11-K o Form 10-Q o Form 10-D o Form N-SAR o Form N-CSR For Period Ended: December 31, 2014 o Transition Report on Form 10-K o Transition Report on Form 20-F o Transition Report on Form 11-K o Transition Report on Form 10-Q o Transition Report o |
|
| January 12, 2015 |
SC 13G/A 1 form13ga2.htm WEXFORD CAPITAL LP SC 13G A2 1-12-15 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G A/2 UNDER THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO.2) Oncovista Innovative Therapies, Inc. (Name of Issuer) Common Shares (Title of Class of Securities) 68232J105 (CUSIP Number) December 31, 2014 (Date of Event which Requires Filing of this Sta |
|
| November 13, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2014 ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-28347 ONCOVIST |
|
| August 12, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2014 ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-28347 ONCOVISTA INN |
|
| June 19, 2014 |
OVIT / OncoVista Innovative Therapies, Inc. / Smithline Richard Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) Amendment No. 8 INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1 (b) (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2 OncoVista Innovative Therapies, Inc. (Name of Issuer) Common Stock, $0.001par value per share (Title of Class of Securities) 68232J105 (CUSIP Number) June 16, |
|
| May 9, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2014 ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-28347 ONCOVISTA IN |
|
| April 14, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2013 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-28347 ONCOVISTA INNOVAT |
|
| March 28, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check one): x Form 10-K o Form 20-F o Form 11-K o Form 10-Q o Form 10-D o Form N-SAR o Form N-CSR For Period Ended: December 31, 2013 o Transition Report on Form 10-K o Transition Report on Form 20-F o Transition Report on Form 11-K o Transition Report on Form 10-Q o Transition Report o |
|
| February 14, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G A/1 UNDER THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO.1) Oncovista Innovative Therapies, Inc. (Name of Issuer) Common Shares (Title of Class of Securities) 68232J105 (CUSIP Number) December 31, 2013 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursua |
|
| January 31, 2014 |
OVIT / OncoVista Innovative Therapies, Inc. / Smithline Richard Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) Amendment No. 7 INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1 (b) (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2 OncoVista Innovative Therapies, Inc. (Name of Issuer) Common Stock, $0.001par value per share (Title of Class of Securities) 68232J105 (CUSIP Number) January |
|
| November 14, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2013 ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-28347 ONCOVIST |
|
| August 14, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2013 ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-28347 ONCOVISTA INN |
|
| May 14, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2013 ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-28347 ONCOVISTA IN |
|
| April 1, 2013 |
10-K 1 v33864010k.htm FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2012 ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file num |
|
| February 14, 2013 |
OVIT / OncoVista Innovative Therapies, Inc. / Smithline Richard Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) Amendment No. 6 INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1 (b) (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2 OncoVista Innovative Therapies, Inc. (Name of Issuer) Common Stock, $0.001par value per share (Title of Class of Securities) 68232J105 (CUSIP Number) February |
|
| November 7, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2012 ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-28347 ONCOVIST |
|
| August 14, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2012 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-28347 ONCOVISTA |
|
| May 15, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2012 ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-28347 ONCOVISTA IN |
|
| March 30, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2011 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-28347 ONCOVISTA INNOVAT |
|
| March 14, 2012 |
OVIT / OncoVista Innovative Therapies, Inc. / Smithline Richard Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) Amendment No. 5 INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1 (b) (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2 OncoVista Innovative Therapies, Inc. (Name of Issuer) Common Stock, $0.001par value per share (Title of Class of Securities) 68232J105 (CUSIP Number) March 9, |
|
| February 10, 2012 |
OVIT / OncoVista Innovative Therapies, Inc. / Smithline Richard Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) Amendment No. 4 INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1 (b) (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2 OncoVista Innovative Therapies, Inc. (Name of Issuer) Common Stock, $0.001par value per share (Title of Class of Securities) 68232J105 (CUSIP Number) February |
|
| November 14, 2011 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2011 ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-28347 ONCOVIST |
|
| August 15, 2011 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2011 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-28347 ONCOVISTA INN |
|
| May 12, 2011 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2011 ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-28347 ONCOVISTA IN |
|
| May 12, 2011 |
AMENDMENT TO MEDIA ADVERTISING AGREEMENT EX-10.1 2 v221480ex10-1.htm EX-10.1 AMENDMENT TO MEDIA ADVERTISING AGREEMENT The following provisions (the “Amendment”) are hereby incorporated into, and are hereby made a part of, that certain Media Advertising Agreement, dated February 8, 2011 (the “Agreement”), by and between MJD Media, LLC, a New York limited liability company (“Consultant”) and OncoVista Innovative Therapies, Inc., a Nevada c |
|
| March 31, 2011 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2010 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-28347 ONCOVISTA INNOVAT |
|
| March 31, 2011 |
Media Advertising Agreement This Agreement (?The Agreement?) is made this 8 th day of Febuary 2011, by and between MJD Media LLC. |
|
| March 31, 2011 |
EMPLOYEE EMPLOYMENT AGREEMENT THIS EMPLOYEE EMPLOYMENT AGREEMENT (the “Agreement”) is made, entered into, and effective as of November 1, 2010 (“Effective Date”) by and between OncoVista Innovative Therapies, Inc. |
|
| March 31, 2011 |
Exhibit 21.1 LIST OF SUBSIDIARIES Name State of Incorporation OncoVista, Inc. (100% owned) Delaware OncoVista-Aengus, Inc.* (100% owned) Delaware NanoVici, Inc.* (100% owned) Delaware * Subsidiary of OncoVista, Inc. |
|
| March 31, 2011 |
EX-10.46 13 v216517ex10-46.htm NEW MILLENNIUM PR COMMUNICATIONS 124 W. 79th Street, Ste. 2C New York, New York 10024 PUBLIC RELATIONS /MEDIA SERVICES CONTRACT Monday, January 31, 2011 Alexander L. Weis, PhD Chairman, CEO & President OncoVista Innovative Therapies, Inc. 14785 Omicron Drive, Suite 104 San Antonio, Texas 78245-3222 Dear Alex: We are delighted to submit this contract for public relati |
|
| March 31, 2011 |
EXECUTIVE EMPLOYMENT AGREEMENT EX-10.40 2 v216517ex10-40.htm EXECUTIVE EMPLOYMENT AGREEMENT THIS EXECUTIVE EMPLOYMENT AGREEMENT (the “Agreement”) is made, entered into, and effective as of January 3, 2011 (“Effective Date”) by and between OncoVista Innovative Therapies, Inc., a Delaware corporation (the “Company”), and Michael Moloney, an individual (the “Executive”). RECITALS WHEREAS, the Company is currently engaged in the de |
|
| March 31, 2011 |
LEASE AGREEMENT BETWEEN LIPITEK INTERNATIONAL, INC., AS LANDLORD, AND ONCOVISTA, INC., AS TENANT DATED JANUARY 3, 2011 BASIC LEASE INFORMATION Lease Date: January 3, 2011 Landlord: Lipitek International, Inc., a Delaware corporation Tenant: Oncovista, Inc., a Delaware corporation Premises: Unit Nos. 1, 2 and 3, containing 5,725 rentable square feet, in the office building commonly known as Texas R |
|
| March 31, 2011 |
EX-10.41 5 v216517ex10-41.htm CONSULTING AGREEMENT This Consulting Agreement (the “Agreement”) dated as of January 3, 2011 is by and between OncoVista Innovative Therapies, Inc., a Nevada corporation (“OncoVista”), and FACT Consulting, LLC, a Texas limited liability company located at 30907 Keeneland Drive, Fair Oaks, Texas 78015 (“Consultant”). RECITALS WHEREAS, OncoVista desires to engage Consul |
|
| March 31, 2011 |
HealthPro BioVentures LLC CONFIDENTIAL January 7, 2010 OncoVista Innovative Therapies, Inc. |
|
| March 10, 2011 |
Exhibit 99.2 COMPANY CONTACT: INVESTOR CONTACT: Michael Moloney Richard Stern Chief Operating Officer Stern & Co 210.677.6000 212.888.0044 OncoVista Innovative Therapies Outlines Business Strategy “Company Is Moving Full-Speed Ahead,” Says CEO Latest Developments: · received first payment from sale of majority holding in its German subsidiary AdnaGen AG; · funding the development of its existing c |
|
| March 10, 2011 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) March 8,2011 ONCOVISTA INNOVATIVE THERAPIES, INC. |
|
| March 10, 2011 |
Exhibit 99.1 March 8, 2011 Dear OncoVista Shareholders, OncoVista Innovative Therapies, Inc. (“OncoVista”) is moving full-speed ahead in executing our strategy to develop targeted, safer and more efficacious cancer treatments with reduced or no toxicity. As a result of the divestiture last November of our majority holding in our German subsidiary AdnaGen AG, OncoVista may receive as much as $64.7 |
|
| February 14, 2011 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) Amendment No. 3 INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1 (b) (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2 OncoVista Innovative Therapies, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 68232J105 (CUSIP Number) Februar |
|
| January 5, 2011 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 5, 2011 ONCOVISTA INNOVATIVE THERAPIES, INC. |
|
| December 23, 2010 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q/A (Amendment No. 2) (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2010 ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number |
|
| December 23, 2010 |
FOIA CONFIDENTIAL TREATMENT REQUESTED PORTIONS OF THE EXHIBIT HERETO MARKED BY [**Redacted**] HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION 28 October 2010 Execution Copy Confidential and privileged Stock Purchase Agreement as of 28 October 2010 Table of content: 1. |
|
| December 23, 2010 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q/A (Amendment No. 1) (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2010 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number |
|
| December 23, 2010 |
EX-10.1.B 2 v206428ex10-1b.htm FOIA CONFIDENTIAL TREATMENT REQUESTED PORTIONS OF THE EXHIBIT HERETO MARKED BY [**Redacted**] HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION 28 October 2010 Execution Copy Confidential and privileged Stock Purchase Agreement as of 28 October 2010 Table of content: 1.1 Stocks owned by Sel |
|
| November 15, 2010 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2010 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-28347 ONCOVIST |
|
| November 15, 2010 |
FOIA CONFIDENTIAL TREATMENT REQUESTED Exhibit 10.1 FOIA CONFIDENTIAL TREATMENT REQUESTED PORTIONS OF THE EXHIBIT HERETO MARKED BY [**Redacted**] HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION 28 October 2010 Execution Copy Confidential and privileged Stock Purchase Agreement as of 28 October 2010 Table of content: 1.1 Stocks owned by Sellers 7 1.2 Stocks |
|
| November 3, 2010 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 3, 2010 ONCOVISTA INNOVATIVE THERAPIES, INC. |
|
| August 16, 2010 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2010 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-28347 ONCOVISTA INN |
|
| July 22, 2010 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) July 22, 2010 OncoVista Innovative Therapies, Inc. (Exact name of registrant as specified in its charter) Nevada 000-27629 23-2426437 (State or other jurisdiction of incorporation) (Co |
|
| May 14, 2010 | ||
| May 14, 2010 |
v184616ex10-2 - Converted by SECPublisher 2.1.1.8, created by BCL Technologies Inc., for SEC Filing |
|
| May 14, 2010 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2010 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-28347 ONCOVISTA IN |
|
| March 31, 2010 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2009 ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-28347 ONCOVISTA INNOVAT |
|
| February 16, 2010 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 16, 2010 OncoVista Innovative Therapies, Inc. (Exact name of registrant as specified in its charter) Nevada 000-27629 23-2426437 (State or other jurisdiction of incorporation) |
|
| February 16, 2010 |
EX-10.1 2 v174642ex10-1.htm FORM OF LETTER AGREEMENT EXHIBIT 10.1 ONCOVISTA INNOVATIVE THERAPIES, INC. ONCOVISTA, INC. 14785 Omicron Drive, Suite 104 San Antonio, Texas 78245 January 15, 2010 To the holders (the “Holders”) of the Secured Promissory Notes, dated January 15, 2009 (the “Notes”), by OncoVista Innovative Therapies, Inc., a Nevada corporation (“OIT”), and OncoVista, Inc., a Delaware cor |
|
| February 9, 2010 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) Amendment No. 2 INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1 (b) (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2 OncoVista Innovative Therapies, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 68232J105 (CUSIP Number) Februar |
|
| November 16, 2009 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2009 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-28347 ONCOVIST |
|
| September 21, 2009 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2009 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-28347 ONCOVISTA INN |
|
| May 20, 2009 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2009 ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-28347 ONCOVISTA IN |
|
| May 15, 2009 |
U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 12b-25 U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC FILE NUMBER 000-28347 CUSIP NUMBER 68232J105 (Check One): o Form 10-K and Form 10-KSB o Form 20-F x Form 10-Q and 10-QSB o Form N-SAR For Period Ended: March 31, 2009 o Transition Report on Form 10-K o Transition Report on Form 20-F o Transition Report on Form 11-K o Transition Report on Form |
|
| March 30, 2009 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2008 ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-28347 ONCOVISTA INNOVAT |
|
| March 30, 2009 |
ONCOVISTA INNOVATIVE THERAPIES, INC. Warrants for the Purchase Execution Version NEITHER THE SECURITIES REPRESENTED HEREBY, NOR THE SECURITIES ISSUABLE UPON THE EXERCISE HEREOF, HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), OR ANY STATE SECURITIES LAWS AND MAY NOT BE OFFERED, SOLD, PLEDGED, ASSIGNED, OR OTHERWISE DISPOSED OF UNLESS (1) A REGISTRATION STATEMENT WITH RESPECT THERETO IS EFFECTIVE UNDER THE SECURITIES A |
|
| March 30, 2009 |
Execution Version ONCOVISTA INNOVATIVE THERAPIES, INC. 14785 Omicron Drive, Suite 104 San Antonio, Texas 78245 January 15, 2009 To the holders (including any successors and permitted transferees and assignees of such holders, the “Holders”) of warrants (the “Warrants”) to purchase up to an amount or number of the securities offered in the first Qualified Financing (as defined in the Warrant) (the |
|
| March 30, 2009 |
Secured Promissory Note OncoVista Innovative Therapies, Inc. OncoVista, Inc. Execution Version THIS SECURED PROMISSORY NOTE (THE “NOTE”) HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR ANY OTHER APPLICABLE FEDERAL OR STATE SECURITIES LAWS, AND HAS BEEN ISSUED AND SOLD IN RELIANCE UPON EXEMPTIONS FROM THE REGISTRATION REQUIREMENTS OF SUCH LAWS, INCLUDING, WITHOUT LIMITATION, THE EXEMPTION CONTAINED IN SECTION 4(2) OF THE SECURITIES ACT. |
|
| January 22, 2009 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 15, 2009 OncoVista Innovative Therapies, Inc. (Exact name of registrant as specified in its charter) Nevada 000-28347 33-0881303 (State or other jurisdiction of incorporation) |
|
| November 14, 2008 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2008 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-28347 ONCOVIST |
|
| August 14, 2008 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2008 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-28347 ONCOVISTA INN |
|
| May 15, 2008 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2008 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-28347 ONCOVISTA IN |
|
| May 2, 2008 |
Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A AMENDMENT TO CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 11, 2008 OncoVista Innovative Therapies, Inc. (Exact name of registrant as specified in its charter) Nevada 000-28347 33-0881303 (State or other jurisdiction of |
|
| May 2, 2008 |
Exhibit 16.2 Stan J.H. Lee, CPA 2160 North Central Rd Suite 203 tFort Lee t NJ 07024 794 Broadway t Chula Vista t CA 91910 619-623-7799 Fax 619-564-3408 E-mail) [email protected] April 30, 2008 Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549 Dear Sirs and Madams: We have read Item 4.01 of Form 8-K dated April 29, 2008, of OncoVista Innovative Therapies, Inc. and are in ag |
|
| May 2, 2008 |
Exhibit 16.1 Stan J.H. Lee, CPA 2160 North Central Rd Suite 203 tFort Lee t NJ 07024 794 Broadway t Chula Vista t CA 91910 619-623-7799 Fax 619-564-3408 E-mail) [email protected] April 9, 2008 Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549 Dear Sirs and Madams: We have read Item 4.01 of Form 8-K dated March 31, 2008, of OncoVista Innovative Therapies, Inc. and are in agr |
|
| May 1, 2008 |
Exhibit 16.1 April 30, 2008 Office of the Chief Accountant Securities and Exchange Commission 100 F Street, NE Washington, DC 20549 Re: OncoVista Innovative Therapies, Inc. File Reference No. 000-28347 We were previously the independent registered public accounting firm for OncoVista Innovative Therapies, Inc. and under the date of April 7, 2008, we reported on the financial statements of OncoVist |
|
| May 1, 2008 |
Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A AMENDMENT TO CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 23, 2008 OncoVista Innovative Therapies, Inc. (Exact name of registrant as specified in its charter) Nevada 000-28347 33-0881303 (State or other jurisdiction of i |
|
| April 29, 2008 |
Changes in Registrant's Certifying Accountant UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 23, 2008 OncoVista Innovative Therapies, Inc. (Exact name of registrant as specified in its charter) Nevada 000-28347 33-0881303 (State or other jurisdiction of incorporation) ( |
|
| April 14, 2008 |
EX-21.1 3 v110508ex21-1.htm LIST OF SUBSIDIARIES Name State of Incorporation OncoVista, Inc. (100% owned) Delaware AdnaGen AG* (85% owned) Germany OncoVista-Aengus, Inc.* (100% owned) Delaware NanoVici, Inc.* (100% owned) Delaware * Subsidiary of OncoVista, Inc. |
|
| April 14, 2008 |
CODE OF BUSINESS CONDUCT AND ETHICS ONCOVISTA INNOVATIVE THERAPIES, INC. EX-14.1 2 v110508ex14-1.htm CODE OF BUSINESS CONDUCT AND ETHICS OF ONCOVISTA INNOVATIVE THERAPIES, INC. Effective Date: March 15, 2008 INTRODUCTION ONCOVISTA INNOVATIVE THERAPIES, INC. expects that directors, officers, employees, team members and contract staff members will conduct themselves ethically and properly as a matter of course and comply with the guidelines set forth below. This Code of |
|
| April 14, 2008 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-KSB (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2007 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-28347 ONCOVISTA INNOV |
|
| March 31, 2008 |
Changes in Registrant's Certifying Accountant UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 11, 2008 OncoVista Innovative Therapies, Inc. (Exact name of registrant as specified in its charter) Nevada 000-28347 33-0881303 (State or other jurisdiction of incorporation) |
|
| March 31, 2008 |
U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC FILE NUMBER 000-28347 CUSIP NUMBER 68232J105 (Check One): [ X ] Form 10-K and Form 10-KSB [ ] Form 20-F [ ] Form 10-Q and 10-QSB [ ] Form N-SAR For Period Ended: December 31, 2007 [ ] Transition Report on Form 10-K [ ] Transition Report on Form 20-F [ ] Transition Report on Form 11-K [ ] Tran |
|
| March 6, 2008 | ||
| March 6, 2008 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 5, 2008 OncoVista Innovative Therapies, Inc. (Exact name of registrant as specified in its charter) Nevada 000-28347 23-2426437 (State or other jurisdiction of incorporation) (C |
|
| January 18, 2008 |
Reg. No. 333-147360 Filed pursuant to Rule 424(b)(3) 5,132,417 Shares ONCOVISTA INNOVATIVE THERAPIES, INC. (formerly Aviation Upgrade Technologies, Inc.) Common Stock This is an offering (the “Offering”) of up to an aggregate of 5,132,417 shares of common stock, $0.001 par value, of OncoVista Innovative Therapies, Inc., a Nevada corporation (formerly Aviation Upgrade Technologies, Inc.) (“we”, “us |
|
| January 17, 2008 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 30, 2007 OncoVista Innovative Therapies, Inc. (Exact name of registrant as specified in its charter) Nevada 000-28347 23-2426437 (State or other jurisdiction of incorporation |
|
| January 17, 2008 | ||
| January 17, 2008 | ||
| January 14, 2008 |
ONCOVISTA INNOVATIVE THERAPIES, INC. CHANGES NAME FROM AVIATION UPGRADE TECHNOLOGIES EFFECTIVE JANUARY 8, 2008 NEW TICKER SYMBOL ?OVIT? EFFECTIVE JANUARY 14, 2008 SAN ANTONIO - In December, 2007, the Board of Directors and the holders of a majority of the outstanding common stock of Aviation Upgrade Technologies, Inc. (OTC BB: AVUG.OB), resolved to amend the corporate charter of Aviation Upgrade T |
|
| January 14, 2008 |
Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 2) CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 13, 2007 OncoVista Innovative Therapies, Inc. (Exact name of registrant as specified in its charter) Nevada 000-28347 23-2426437 (State or other jurisdict |
|
| January 14, 2008 |
Exhibit 99.1 ONCOVISTA, INC. AND SUBSIDIARY Index September 30, 2007 Page Consolidated Balance Sheet as of September 30, 2007 (Unaudited) F-1 Consolidated Statements of Operations for the Nine Months Ended September 30, 2007 and 2006 (Unaudited) F-2 Consolidated Statements of Cash Flows for the Nine Months Ended September 30, 2007 and 2006 (Unaudited) F-3 Notes to Consolidated Financial Statements |
|
| January 14, 2008 |
Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 14, 2008 OncoVista Innovative Therapies, Inc. (Exact name of registrant as specified in its charter) Nevada 000-28347 23-2426437 (State or other jurisdiction of incorporation) |
|
| January 10, 2008 |
OncoVista Innovative Therapies, Inc. 14785 Omicron Drive, Suite 104, San Antonio, Texas 78245 January 10, 2008 Securities and Exchange Commission 100 F Street, NE Washington DC 20549 Re: OncoVista Innovative Therapies, Inc. (the “Company”) Registration Statement on Form SB-2 (File No. 333-147360) Ladies and Gentlemen: The Company respectfully requests that the above-referenced registration stateme |
|
| January 10, 2008 |
As filed with the Securities and Exchange Commission on January 10, 2008 As filed with the Securities and Exchange Commission on January 10, 2008 File No. 333-147360 SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 PRE-EFFECTIVE AMENDMENT NO. 2 TO FORM SB-2 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ONCOVISTA INNOVATIVE THERAPIES, INC. (formerly Aviation Upgrade Technologies, Inc.)(Exact Name of Registrant as Specified In Its Charter) Nevada 3714 |
|
| January 10, 2008 |
800 Third Avenue, 21st Floor New York, NY 10022-7604 Tel (212) 209-3050 Fax (212) 371-5500 January 10, 2008 Jeffrey P. |
|
| January 10, 2008 |
800 Third Avenue, 21st Floor New York, NY 10022-7604 Tel (212) 209-3050 Fax (212) 371-5500 January 9, 2008 Parsons Behle & Latimer Attn: Shane L. |
|
| January 10, 2008 |
OncoVista Innovative Therapies, Inc. 14785 Omicron Drive, Suite 104, San Antonio, Texas 78245 January 10, 2008 Securities and Exchange Commission 100 F Street, NE Washington DC 20549 Re: OncoVista Innovative Therapies, Inc. (the “Company”) Registration Statement on Form SB-2 (File No. 333-147360) Ladies and Gentlemen: The Company respectfully requests that the above-referenced registration stateme |
|
| January 10, 2008 |
As filed with the Securities and Exchange Commission on January 10, 2008 As filed with the Securities and Exchange Commission on January 10, 2008 File No. 333-147360 SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 PRE-EFFECTIVE AMENDMENT NO. 3 TO FORM SB-2 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ONCOVISTA INNOVATIVE THERAPIES, INC. (formerly Aviation Upgrade Technologies, Inc.) (Exact Name of Registrant as Specified In Its Charter) Nevada 3714 |
|
| January 9, 2008 |
Sincerely, /s/ Gary Emmanuel Gary Emmanuel January 9, 2008 Jeffrey P. Riedler Assistant Director Securities and Exchange Commission Division of Corporate Finance 100 F Street, N.E. Mail Stop 6010 Washington, D.C. 20549 Re: Aviation Upgrade International, Inc. Registration Statement on Form SB-2 Filed November 13, 2007 File No. 333-147360 Dear Mr. Riedler: On behalf of OncoVista Innnovative Therapies, Inc. (formerly Aviation Upgrade Technol |
|
| January 9, 2008 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 3, 2008 OncoVista Innovative Therapies, Inc. (Exact name of registrant as specified in its charter) Nevada 000-27629 23-2426437 (State or other jurisdiction of incorporation) |
|
| January 9, 2008 | ||
| January 9, 2008 |
EX-21.1 3 v093447ex21-1.htm Exhibit 21.1 LIST OF SUBSIDIARIES Name State of Incorporation OncoVista, Inc. (100% owned) Delaware AdnaGen AG* (85% owned) Germany OncoVista-Aengus, Inc.* (100% owned) Delaware NanoVici, Inc.* (100% owned) Delaware * Subsidiary of OncoVista, Inc. |
|
| January 9, 2008 |
As filed with the Securities and Exchange Commission on January 9, 2008 As filed with the Securities and Exchange Commission on January 9, 2008 File No. 333-147360 SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 PRE-EFFECTIVE AMENDMENT NO. 1 TO FORM SB-2 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ONCOVISTA INNOVATIVE THERAPIES, INC. (formerly Aviation Upgrade Technologies, Inc.) (Exact Name of Registrant as Specified In Its Charter) Nevada 3714 |
|
| January 8, 2008 | ||
| January 8, 2008 |
ONCOVISTA INNOVATIVE THERAPIES, INC. APPOINTS J. MICHAEL EDWARDS NEW CHIEF FINANCIAL OFFICER EXHIBIT 99.1 COMPANY CONTACT: INVESTOR CONTACT: Alexander L. Weis, Ph.D. Porter, LeVay & Rose, Inc. Chief Executive Officer Michael Porter (210) 677-6000 (212) 564-4700 ONCOVISTA INNOVATIVE THERAPIES, INC. APPOINTS J. MICHAEL EDWARDS NEW CHIEF FINANCIAL OFFICER SAN ANTONIO, TX (January 8, 2008) - OncoVista Innovative Therapies, Inc. (OTC BB: AVUG.OB) announced the appointment of J. Michael Edwards |
|
| January 8, 2008 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 2, 2008 OncoVista Innovative Therapies, Inc. (Exact name of registrant as specified in its charter) Nevada 000-27629 23-2426437 (State or other jurisdiction of incorporation) |
|
| December 14, 2007 |
SCHEDULE 14C INFORMATION Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 Check the appropriate box: o Preliminary Information Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14c-5(d)(2)) x Definitive Information Statement Aviation Upgrade Technologies, Inc. |
|
| December 7, 2007 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14F-1 Information Statement Pursuant To Section 14(f) of the Securities Exchange Act of 1934 and Rule 14f-1 Under the Securities Exchange Act of 1934 AVIATION UPGRADE TECHNOLOGIES, INC. (Exact name of registrant as specified in its charter) Nevada 3714 33-0881303 (State or other jurisdiction of incorporation) (Primary |
|
| December 4, 2007 |
SCHEDULE 14C INFORMATION Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 Check the appropriate box: x Preliminary Information Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14c-5(d)(2)) o Definitive Information Statement Aviation Upgrade Technologies, Inc. |
|
| December 3, 2007 | ||
| December 3, 2007 | ||
| December 3, 2007 |
Marlon Nurse, VP - Investor Relations Jeffrey Myhre, VP - Editorial Seven Penn Plaza ? New York, NY 10001 ? 212-564-4700 ? FAX 212-244-3075 ? www. |
|
| December 3, 2007 | ||
| December 3, 2007 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 27, 2007 Aviation Upgrade Technologies, Inc. (Exact name of registrant as specified in its charter) Nevada 000-27629 23-2426437 (State or other jurisdiction of incorporation) |
|
| December 3, 2007 | ||
| December 3, 2007 | ||
| December 3, 2007 | ||
| November 21, 2007 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDED SCHEDULE 13D Under the Securities Exchange Act of 1934 Amendment No. 1* AVIATION UPGRADE TECHNOLOGIES, INC. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 05367W105 (CUSIP Number) OncoVista, Inc. 14785 Omicron Drive, Suite 104 San Antonio, TX 78245 (210) 667-6000 (Name, Address and Telep |
|
| November 21, 2007 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. )* AVIATION UPGRADE TECHNOLOGIES, INC. - (Name of Issuer) Common Stock - (Title of Class of Securities) 05367W105 - (CUSIP Number) November 13, 2007 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pur |
|
| November 20, 2007 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-QSB/A (Mark One) x QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2007 o TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission file number: 0-27689 AVIATION UPGRADE T |
|
| November 19, 2007 | ||
| November 19, 2007 | ||
| November 19, 2007 | ||
| November 19, 2007 | ||
| November 19, 2007 |
ONCOVISTA, INC. AND SUBSIDIARY Consolidated Balance Sheet June 30, 2007 (Unaudited) ONCOVISTA, INC. AND SUBSIDIARY Consolidated Balance Sheet June 30, 2007 (Unaudited) Current Assets: Cash $ 1,228,440 Accounts receivable 45,374 Inventory 34,777 Other current assets 36,861 Total current assets 1,345,452 Equipment, net 204,019 Other Assets 73,113 Total Assets $ 1,622,584 Liabilities Current Liabilities: Cash overdraft $ 23,459 Accounts payable 69,490 Accrued expenses 425,818 Refund |
|
| November 19, 2007 | ||
| November 19, 2007 | ||
| November 19, 2007 | ||
| November 19, 2007 |
OncoVista, Inc. 2007 STOCK OPTION PLAN FOR INDEPENDENT AND NON-EMPLOYEE DIRECTORS Exhibit 10.32 OncoVista, Inc. 2007 STOCK OPTION PLAN FOR INDEPENDENT AND NON-EMPLOYEE DIRECTORS 1. Purpose The purpose of the 2007 OncoVista, Inc. Stock Option Plan for Independent and Non-Employee Directors (the ?Plan?) is to promote the interests of OncoVista, Inc., a Delaware corporation (the ?Company?), and its stockholders by increasing the proprietary and vested interest of independent and n |
|
| November 19, 2007 | ||
| November 19, 2007 | ||
| November 19, 2007 |
OncoVista, Inc. 2007 STOCK OPTION PLAN Exhibit 10.31 OncoVista, Inc. 2007 STOCK OPTION PLAN 1. Purposes of the Plan. The purposes of this Stock Option Plan are to attract and retain the best available personnel for positions of substantial responsibility, to provide additional incentive to Employees, Directors and Consultants and to promote the success of the Company's business. Options granted under the Plan may be Incentive Stock Opt |
|
| November 19, 2007 | ||
| November 19, 2007 | ||
| November 19, 2007 | ||
| November 19, 2007 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-QSB (Mark One) x QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2007 o TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission file number: 0-27689 AVIATION UPGRADE TEC |
|
| November 19, 2007 |
ONCOVISTA, INC. AND SUBSIDIARY Consolidated Financial Statements Years Ended December 31, 2006 and 2005 ONCOVISTA, INC. AND SUBSIDIARY Index December 31, 2006 Page Report of Independent Registered Public Accounting Firm 1 Consolidated Balance Sheet as of December 31, 2006 2 Consolidated Statements of Operations for the Years Ended December 31, 2006 and 2005 3 Consolidated Statement of Changes in S |
|
| November 19, 2007 | ||
| November 19, 2007 | ||
| November 19, 2007 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 13, 2007 Aviation Upgrade Technologies, Inc. (Exact name of registrant as specified in its charter) Nevada 000-27629 23-2426437 (State or other jurisdiction of incorporation |
|
| November 19, 2007 | ||
| November 19, 2007 | ||
| November 19, 2007 | ||
| November 19, 2007 | ||
| November 19, 2007 | ||
| November 19, 2007 | ||
| November 13, 2007 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 13, 2007 Aviation Upgrade Technologies, Inc. (Exact name of registrant as specified in its charter) Nevada 000-27629 23-2426437 (State or other jurisdiction of incorporation) |
|
| November 13, 2007 | ||
| November 13, 2007 |
Exhibit 21.1 LIST OF SUBSIDIARIES Name State of Incorporation OncoVista, Inc. (100% owned) Delaware AdnaGen AG* (51% owned) Germany OncoVista-Aengus, Inc.* (100% owned) Delaware NanoVici, Inc.* (100% owned) Delaware * Subsidiary of OncoVista, Inc. |
|
| November 13, 2007 | ||
| November 13, 2007 |
STATE OF DELAWARE CERTIFICATE OF MERGER OF DOMESTIC CORPORATIONS STATE OF DELAWARE CERTIFICATE OF MERGER OF DOMESTIC CORPORATIONS Pursuant to Title 8, Section 251(c) of the Delaware General Corporation Law, the undersigned corporation executed the following Certificate of Merger: FIRST: The name of the surviving corporation is OncoVista, Inc. |
|
| November 13, 2007 |
ONCOVISTA, INC. AND SUBSIDIARY Consolidated Balance Sheet June 30, 2007 (Unaudited) ONCOVISTA, INC. AND SUBSIDIARY Consolidated Balance Sheet June 30, 2007 (Unaudited) Current Assets: Cash $ 1,228,440 Accounts receivable 45,374 Inventory 34,777 Other current assets 36,861 Total current assets 1,345,452 Equipment, net 204,019 Other Assets 73,113 Total Assets $ 1,622,584 Liabilities Current Liabilities: Cash overdraft $ 23,459 Accounts payable 69,490 Accrued expenses 425,818 Refund |
|
| November 13, 2007 | ||
| November 13, 2007 |
v090936ex10-6 - Converted by SECPublisher 2.1.1.8, created by BCL Technologies Inc., for SEC Filing |
|
| November 13, 2007 |
As filed with the Securities and Exchange Commission on November 13, 2007 As filed with the Securities and Exchange Commission on November 13, 2007 File No. |
|
| November 13, 2007 |
ONCOVISTA, INC. AND SUBSIDIARY Consolidated Financial Statements Years Ended December 31, 2006 and 2005 ONCOVISTA, INC. AND SUBSIDIARY Index December 31, 2006 Page Report of Independent Registered Public Accounting Firm 1 Consolidated Balance Sheet as of December 31, 2006 2 Consolidated Statements of Operations for the Years Ended December 31, 2006 and 2005 3 Consolidated Statement of Changes in S |
|
| November 13, 2007 |
Exhibit 21.1 LIST OF SUBSIDIARIES Name State of Incorporation OncoVista, Inc. (100% owned) Delaware AdnaGen AG* (51% owned) Germany OncoVista-Aengus, Inc.* (100% owned) Delaware NanoVici, Inc.* (100% owned) Delaware * Subsidiary of OncoVista, Inc. |
|
| November 13, 2007 | ||
| November 13, 2007 | ||
| November 13, 2007 |
v090936ex3-1 - Converted by SECPublisher 2.1.1.8, created by BCL Technologies Inc., for SEC Filing |
|
| October 29, 2007 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) October 26, 2007 Aviation Upgrade Technologies, Inc. (Exact name of registrant as specified in its charter) Nevada 000-27629 23-2426437 (State or other jurisdiction of incorporation) ( |
|
| October 29, 2007 |
AVIATION UPGRADE TECHNOLOGIES ENTERS INTO MERGER AGREEMENT WITH ONCOVISTA, INC. COMPANY CONTACT: INVESTOR CONTACT: Alexander L. Weis, Ph.D. Porter, LeVay & Rose, Inc. Chief Executive Officer Michael Porter (210) 677-6000 (212) 564-4700 FOR IMMEDIATE RELEASE AVIATION UPGRADE TECHNOLOGIES ENTERS INTO MERGER AGREEMENT WITH ONCOVISTA, INC. SAN ANTONIO, TX, October 26, 2007 - On October 26, 2007, Aviation Upgrade Technologies, Inc. (OTC BB: AVUG.ob), and its newly-formed wholly-ow |
|
| October 29, 2007 |
Phase I Phase II Phase III AdnaGen Oncology Diagnostics* Company Overview October 2007 0 Safe Harbor Statement Certain matters discussed in this press release are “forward-looking statements” intended to qualify for the safe harbors from liability established by the Private Securities Litigation Reform Act of 1995. |
|
| October 29, 2007 |
AGREEMENT AND PLAN OF MERGER, DATED AS OF OCTOBER 26, 2007 AMONG AVIATION UPGRADE TECHNOLOGIES, INC. |
|
| October 24, 2007 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) October 22, 2007 Aviation Upgrade Technologies, Inc. (Exact name of registrant as specified in its charter) Nevada 000-27629 23-2426437 (State or other jurisdiction of incorporation) ( |
|
| October 24, 2007 |
EX-3.1 2 v091176ex3-1.htm |
|
| October 22, 2007 |
U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-KSB AMENDMENT NO. 2 U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-KSB AMENDMENT NO. 2 (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934: For the fiscal year ended December 31, 2006 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934: For the transition period fromto. Commission File Number 0-28347 AVIATION |
|
| October 22, 2007 |
Abrams Garfinkel Margolis Bergson, LLP Attorneys at Law 4100 Newport Place Drive Suite 830 Newport Beach, CA 92660 telephone: (949) 250-8655 facsimile: (949) 250-8656 www. |
|
| October 22, 2007 |
Aviation Upgrade Technologies, Inc. 14785 Omicron Drive, Suite 104 San Antonio, TX 78245 October 22, 2007 AS FILED ON EDGAR AND VIA REGULAR U.S. MAIL Division of Corporation Finance Securities and Exchange Commission 100 F Street N.E. Washington, D.C. 20549 Mail Stop 3561 Attn: Beverly A. Singleton Re: Aviation Upgrade Technologies, Inc., a Nevada corporation Supplemental response letter dated Sep |
|
| October 17, 2007 |
8-K 1 v0905318k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) October 12, 2007 Aviation Upgrade Technologies, Inc. (Exact name of registrant as specified in its charter) Nevada 000-27629 23-2426437 (State or other jurisdiction |
|
| September 25, 2007 |
SCHEDULE 14C INFORMATION Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 Check the appropriate box: x Preliminary Information Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14c-5(d)(2)) o Definitive Information Statement Aviation Upgrade Technologies, Inc. |
|
| September 17, 2007 |
U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 AMENDMENT NO. 1 TO FORM 10-QSB U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 AMENDMENT NO. 1 TO FORM 10-QSB (Mark One) [x] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2007 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number 0-276 |
|
| September 17, 2007 |
U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-KSB AMENDMENT NO. 1 U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-KSB AMENDMENT NO. 1 (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934:For the fiscal year ended December 31, 2006 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934:For the transition period fromto. Commission File Number 0-28347 AVIATION UP |
|
| September 14, 2007 |
ABRAMS GARFINKEL MARGOLIS BERGSON, LLP Attorneys at Law 4100 Newport Place Drive, Suite 830 Newport Beach, California 92660 Telephone (949) 250-8655 Facsimile: (949) 250-8656 www. |
|
| September 14, 2007 |
Aviation Upgrade Technologies, Inc. 14785 Omicron Drive, Suite 104 San Antonio, TX 78245 September 14, 2007 AS FILED ON EDGAR AND VIA REGULAR U.S. MAIL Division of Corporation Finance Securities and Exchange Commission 100 F Street N.E. Washington, D.C. 20549 Mail Stop 3561 Attn: Beverly A. Singleton Re: Aviation Upgrade Technologies, Inc., a Nevada corporation Supplemental response letter dated A |
|
| August 27, 2007 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 Aviation Upgrade Technologies, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 05367W105 (CUSIP Number) OncoVista, Inc. 14785 Omicron Drive, Suite 104 San Antonio, TX 78245 (210) 667-6000 (Name, Address and Telephone Number of Person Aut |
|
| August 22, 2007 |
SHARE SALE/PURCHASE AGREEMENT To: The Person listed on the Counterpart Signature Page hereof (the "Seller") Re: Purchase of shares that are "free-trading" (the "Common Stock") of Aviation Upgrade Technologies, Inc. |
|
| August 22, 2007 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 16, 2007 Aviation Upgrade Technologies, Inc. (Exact name of registrant as specified in its charter) Nevada 000-27629 23-2426437 (State or other jurisdiction of incorporation) (C |
|
| August 22, 2007 |
SECURITIES PURCHASE AGREEMENT, dated as of August 16, 2007 (the ?Agreement?), among ONCOVISTA, INC. |
|
| August 16, 2007 |
U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-QSB U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-QSB (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934: For the quarterly period ended June 30, 2007 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934: For the transition period from to. Commission File Number 0-27689 Aviation Upgrade Tec |
|
| August 14, 2007 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 (Check One): oForm 10-K oForm 20-F oForm 11-K xForm 10-Q oForm N-SAR For Period Ended: June 30, 2007 [ ] Transition Report on Form 10-K [ ] Transition Report on Form 20-F [ ] Transition Report on Form 11-K [ ] Transition Report on Form 10-Q [ ] Transition Report on Form N-SAR For the Transition Period Ended: Read Instruction ( |
|
| August 10, 2007 |
August 10, 2007 VIA REGULAR U.S. MAIL Division of Corporation Finance Securities and Exchange Commission 100 F Street N.E. Washington, D.C. 20549 Mail Stop 3561 Attn: Beverly A. Singleton Re: Aviation Upgrade Technologies, Inc., a Nevada corporation Supplemental response letter dated June 25, 2007 regarding the Form 10-KSB for the year ended December 31, 2006 File 0-28347 Dear Ms. Singleton: On be |
|
| August 9, 2007 |
8-K 1 aviation8k-080507.htm CURRENT REPORT SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 5, 2007 Commission File Number: 00-27689 Aviation Upgrade Technologies, Inc. (Exact name of registrant as specified in its charter) Nevada 33-08813 |
|
| June 27, 2007 |
June 25, 2007 VIA REGULAR U.S. MAIL Division of Corporation Finance Securities and Exchange Commission 100 F Street N.E. Washington, D.C. 20549 Mail Stop 3561 Attn: Beverly A. Singleton Re: Aviation Upgrade Technologies, Inc., a Nevada corporation Form 10-KSB for the year ended December 31, 2006 File 0-28347 Dear Ms. Singleton: On behalf of Aviation Upgrade Technologies, Inc., a Nevada corporation |
|
| May 21, 2007 |
U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-QSB U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-QSB (Mark One) [x] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2007 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 0-27689 Aviation Upgrade T |
|
| May 16, 2007 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 (Check One): oForm 10-K oForm 20-F oForm 11-K xForm 10-Q oForm N-SAR For Period Ended: March 31, 2007 [ ] Transition Report on Form 10-K [ ] Transition Report on Form 20-F [ ] Transition Report on Form 11-K [ ] Transition Report on Form 10-Q [ ] Transition Report on Form N-SAR For the Transition Period Ended: Read Instruction |
|
| April 2, 2007 |
U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-KSB U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-KSB (Mark One) xANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934: For the fiscal year ended December 31, 2006 oTRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934: For the transition period from to . Commission File Number 0-28347 AVIATION UPGRADE TECHNOLO |
|
| March 13, 2007 |
Exhibit 16.1 Chang G. Park, CPA, Ph. D. t 371 E St. t CHULA VISTA, CALIFORNIA 91910 t TEL (619) 691-1566 t DIRECT (858) 722-5953 t FAX (858) 408-2695 t E-Mail [email protected] March 9, 2007 United States Securities and Exchange Commission Division of Corporation Finance 450 Fifth Street, N.W. Washington, D.C: 20549 Dear Sir or Madam: We have read Item 4.01 of Form 8-K dated February 28th, 2007 |
|
| March 13, 2007 |
Changes in Registrant's Certifying Accountant SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 AMENDMENT NO. 1 TO FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 28, 2007 Commission File Number: 00-27689 Aviation Upgrade Technologies, Inc. (Exact name of registrant as specified in its charter) Nevada (State of incorporation or or |
|
| March 2, 2007 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 28, 2007 Commission File Number: 00-27689 Aviation Upgrade Technologies, Inc. (Exact name of registrant as specified in its charter) Nevada 33-0881303 (State of incorporation or organizati |
|
| November 21, 2006 |
Exhibit 16.1 ACI ARMANDO C. IBARRA Certified Public Accountants A Professional Corporation Armando C. Ibarra, C.P.A. Armando Ibarra, Jr., C.P.A., JD Members of the California Society of Certified Public Accountants Members of the American Institute of Certified Public Accountants Registered with the Public Company Accounting Oversight Board November 20, 2006 United States Securities and Exchange C |
|
| November 21, 2006 |
Changes in Registrant's Certifying Accountant SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 AMENDMENT NO 1. TO FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 16, 2006 Commission File Number: 00-27689 (Exact name of registrant as specified in its charter) Nevada Aviation Upgrade Technologies, Inc. 33-0881303 (State of incorpor |
|
| November 20, 2006 |
U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-QSB U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-QSB (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2006 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 0-27689 Aviation Upgrade T |
|
| November 20, 2006 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 16, 2006 Commission File Number: 00-27689 (Exact name of registrant as specified in its charter) Nevada Aviation Upgrade Technologies, Inc. 33-0881303 (State of incorporation or organizati |
|
| November 14, 2006 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC FILE # 000-27689 (Check One): oForm 10-K oForm 20-F oForm 11-K xForm 10-Q oForm N-SAR For Period Ended: September 30, 2006 [ ] Transition Report on Form 10-K [ ] Transition Report on Form 20-F [ ] Transition Report on Form 11-K [ ] Transition Report on Form 10-Q [ ] Transition Report |
|
| September 18, 2006 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 9, 2006 Commission File Number: 0-27689 AVIATION UPGRADE TECHNOLOGIES, INC. (Exact name of registrant as specified in its charter) Nevada (State or other jurisdiction of incorporation or org |
|
| July 18, 2006 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-QSB UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-QSB (Mark One) [ x ] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2006 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0-27689 Aviatio |
|
| May 22, 2006 |
U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-QSB U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-QSB (Mark One) [ x ] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2006 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 0-27689 Aviation Upgrade |
|
| May 15, 2006 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SEC File # 000- 27689 (Check One): o Form 10-K o Form 20-F o Form 11-K x Form 10-Q o Form N-SAR For Period Ended: March 31, 2006 [ ] Transition Report on Form 10-K [ ] Transition Report on Form 20-F [ ] Transition Report on Form 11-K [ ] Transition Report on Form 10-Q [ ] Transition Report on Form N-SAR For the Transition Peri |
|
| February 23, 2006 |
U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-KSB U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-KSB (Mark One) [ x ] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED DECEMBER 31, 2005 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number 0-27689 AVIATION UPGRADE TE |
|
| November 13, 2001 |
U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-QSB (Mark One) [x] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2001 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to - - Commission File Number 0-27689 Aviation U |
|
| July 30, 2001 |
U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-QSB (Mark One) [x] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2001 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 0-27689 Aviation Upgrade Te |
